Sample type Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples
Components
Break apart microtiter test strips each coated single wells
8 x 12 (96 Total)
Lyophilized Standard
2 x vial
Biotin-labeled Antibody(Concentrated, 100X)
120 uL
HRP-Streptavidin Conjugate(Concentrated, 100X)
120 uL
Washing solution concentrate (25X)
30 mL
Sample Dilution buffer
20 mL
Antibody Dilution buffer
10 mL
Streptavidin Dilution buffer
10 mL
Stopping solution
10 mL
TMB Substrate (ready-to-use)
10 mL
Plate seals
3
Storage Store at 2-8°C.
target relevance
anti-Faricimab antibody an autoantibody against anti-Faricimab antibody generated in a administered subject
Faricimab Faricimab biologic drug binds Homo sapiens VEGFA,Homo sapiens ANGPT2
Homo sapiens VEGFA Vascular endothelial growth factor A, long form
Protein names Vascular endothelial growth factor A, long form
Alternative names Vascular permeability factor
Gene names VEGFA
Protein family Belongs to the PDGF/VEGF growth factor family
Function Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)
Subcellular location Secreted
Structure Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042). Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889)
Post-translational modification Produced by use of an alternative upstream CUG codon and post-translationally processed into the N-terminal N-VEGF form and the C-terminal secreted VEGFA form
Involvement in disease Microvascular complications of diabetes 1 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Keywords 3D-structure, Alternative initiation, Alternative promoter usage, Alternative splicing, Angiogenesis, Cytoplasm, Developmental protein, Differentiation, Direct protein sequencing, Disulfide bond, Endoplasmic reticulum, Extracellular matrix, Glycoprotein, Golgi apparatus, Growth factor, Heparin-binding, Mitogen, Nucleus, Proteomics identification, Reference proteome, Secreted
Function Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1 (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal (PubMed:15284220, PubMed:19116766, PubMed:19223473, PubMed:9204896). Involved in the regulation of lymphangiogenesis (PubMed:32908006)
Subcellular location Secreted
Structure Interacts with TEK/TIE2, competing for the same binding site as ANGPT1 (PubMed:12427764, PubMed:15284220, PubMed:19223473, PubMed:32908006, PubMed:9204896). Interacts with ITGA5 (PubMed:32908006). Interacts with SVEP1/polydom (By similarity). Interacts with THBD; this interaction significantly inhibits the generation of activated PC and TAFIa/CPB2 by the thrombin/thrombomodulin complex (PubMed:29323190)
Involvement in disease Lymphatic malformation 10 A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM10 is an autosomal dominant form characterized by the onset of swelling in the lower extremities within the first year of life. Lymphedema may also occur in the neck, upper extremities, and scrotum or labia majora. Gradual resorption generally occurs, although some patients may experience progression complicated by cellulitis. Incomplete penetrance has been observed in some families.
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.